December 2025 in “Dermatology Reports” This source describes vitiligo as a chronic condition marked by the loss of skin pigmentation and discusses leukotrichia, a feature affecting 10% to 60% of cases, which arises from melanocyte loss in hair follicles and appears as well-defined white patches on the skin.
January 2025 in “International Journal of Dermatology Research” This prospective observational study investigated 200 patients with non-scarring alopecia, concluding that accurate classification combined with individualized treatment, including combination therapies, significantly improved outcomes over monotherapy with topical minoxidil.
October 2025 in “Clinical and Experimental Dermatology” In this retrospective study, researchers reported that low-dose oral minoxidil significantly improved hair density in 60 patients with androgenetic alopecia or telogen effluvium over 4-8 months, as detected through standardized AI-powered imaging.
In this study, baseline neutrophil-to-lymphocyte ratio (NLR) was associated with predicting early trichoscopic response in patients undergoing PRP-based treatment for non-scarring alopecia.
September 2024 in “Journal of the American Academy of Dermatology” In this study, patients with severe alopecia areata treated with baricitinib showed continued improvement in scalp hair regrowth from weeks 52 to 152, particularly among those initially responding with eyelash or eyebrow regrowth but not scalp hair, with 39% achieving substantial regrowth by week 104.